Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q13472

UPID:
TOP3A_HUMAN

ALTERNATIVE NAMES:
DNA topoisomerase III alpha

ALTERNATIVE UPACC:
Q13472; A8KA61; B4DK80; D3DXC7; Q13473

BACKGROUND:
The enzyme DNA topoisomerase III alpha is essential for resolving DNA supercoiling during replication and transcription, ensuring genomic stability and proper cell function. It operates by making transient single-strand breaks in the DNA, allowing for the relaxation of supercoils. Beyond its role in nuclear DNA maintenance, it is also critical for mitochondrial DNA segregation and decatenation, showcasing its multifunctional importance in cellular biology.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of DNA topoisomerase 3-alpha could open doors to potential therapeutic strategies. Its direct association with diseases such as Microcephaly, growth restriction, and Progressive external ophthalmoplegia highlights its significance in genetic disorder research. Developing inhibitors or activators targeting this protein could offer new avenues for treating these complex conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.